Amarin Investor Heat Intensifies, Despite ‘Unprecedented’ Vascepa Fortitude
Four Generic Icosapent Ethyl Products Have Only 40% Market Share
The brouhaha between Amarin and its largest shareholder has continued apace, with a smorgasbord of verbal volleys launched against the company, ahead of Amarin’s general meeting of shareholders later this month.
